Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 billion from its type 2 diabetes drug Mounjaro and $1.9 billion from its weight-loss medication Zepbound. Wall Street’s…
US stocks surged on Wednesday, fueled by a slowdown in core inflation and better-than-expected earnings from major banks. The…
As spot Bitcoin exchange-traded funds (ETFs) mark their first anniversary and Ethereum ETFs reach the six-month milestone, the cryptocurrency…
The AUD/USD exchange rate rose slightly after the latest US inflation and Australian jobs data. After bottoming at 0.6133…
Adani Group stocks surged today as Hindenburg Research, the short-selling firm infamous for its critical reports, announced its immediate…
Aluminium prices on the London Metal Exchange have risen sharply over the past couple of sessions after the European…
Shares of Tesla Inc (NASDAQ: TSLA) are priced for perfection following a 100% increase over the past three months.…
Brazilian fintech Nubank has made a strategic move by partnering with Mexican convenience store chain Oxxo, owned by FEMSA.…
Klarna is in focus this morning after announcing a new distribution partnership with Stripe aimed at expanding its footprint…